The N4 Pharma PLC (LON: N4P) share price plunged 28.6% after announcing a new broker offer to raise up to £1.0 million. The offer’s initial target is to raise £0.25 million, but the amount could be extended to the upper figure if the issue is oversubscribed.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Investors reacted negatively to the news given that the new shares were priced at 2 pence each, representing a significant premium to Thrusday’s closing price of 2.80p. The company’s shares had traded at a high of 3.64p in mid-October, demonstrating its potential to trade at higher prices.
Sponsored content
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Sponsored content
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The decline in N4 Pharma’s share price reflected the significant discount offered to the shareholders participating in the offer.
N4 Pharma’s last significant announcement before today’s news was at the beginning of November when it gave an update regarding the patents it had filed in March 2020. The company has filed patents related to its proprietary Nuvec® technology.
The specialist pharmaceutical company noted that Nuvec® could manufacture viral vectors and make viral vectors more efficient in applications such as ex-vivo gene therapy treatments. Therefore, it filed for a Patent Cooperation Treaty (PCT) application.
Sponsored
Moreover, the company decided to update its patent application with a focus on its claims regarding using the specific spiky properties of Nuvec™ to load and transfect viral vectors, especially adenoviral and lentiviral vectors.
The company has filed for patents in the USA, India, Japan, Europe (including the UK), and Canada. The firm also plans to file for patents in Australia and China.
So, will N4 Pharma shares recover from today’s decline? Only time can tell, but any progress the company reports could trigger a rally higher.
*This is not investment advice.
N4 Pharma share price.
The N4 Pharma share price plunged 28.57% to trade at 2.00p, falling from Thursday’s closing price of 2.80p.
Simon ist Autor und Analyst für den Bereich Finanzwesen und blickt auf über sechs Jahre professionelle Erfahrung als Trader zurück. Er absolvierte einen Bachelor in Mathematik und Informatik und hat eine Leidenschaft für die Finanzmärkte. Simon handelt FX, Rohstoffe und Aktien. Er konzentriert sich auf Price Action Trading.
